SCHEMBL891562

SCHEMBL891562

CC1=C(/C=C/C(C)O)C(C)(C)CCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
ALDH1A1 P00352 9/20 0.51
PTGS1 P23219 4/20 0.51
LMNA P02545 2/20 0.51
DRD3 P35462 2/20 0.51
SLCO1B3 Q9NPD5 1/20 0.51
SLCO1B1 Q9Y6L6 1/20 0.51
HAO1 Q9UJM8 1/20 0.49
RXRA P19793 6/20 0.47
CYP3A4 P08684 5/20 0.47
APP P05067 4/20 0.47
SNCA P37840 4/20 0.47
ALOX15 P16050 3/20 0.47
TSHR P16473 2/20 0.47
TP53 P04637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR2E1 Q9Y466 1/20 0.47
MAPT P10636 6/20 0.45
RARA P10276 4/20 0.45
RARB P10826 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997874 1.00 CYP1A2 (0.57) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL11472130 1.00 CYP1A2 (0.57) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL21198720 0.87 CYP1A2 (0.46) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL13749295 0.83 CYP1A2 (0.53) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL7643377 0.82 CYP1A2 (0.53) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL3504278 0.82 CYP1A2 (0.53) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL1183480 0.81 CYP1A2 (0.37) CYP1A2ALDH1A1PTGS1LMNADRD3
Iodide SCHEMBL11765922 0.81 CYP1A2 (0.51) CYP1A2ALDH1A1PTGS1LMNADRD3
Iodide SCHEMBL11765926 0.81 CYP1A2 (0.51) CYP1A2ALDH1A1PTGS1LMNADRD3
SCHEMBL11671414 0.81 ALDH1A1 (0.73) CYP1A2ALDH1A1PTGS1LMNADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711010-A2 PRO-PERFUME COMPOSITIONS Firmenich SA (CH) 2026-03-18 EP claimed
US-12509482-B2 3′-ketoglycoside compound for the slow release of a volatile alcohol GLYCOSCIENCE, S.L. (ES) 2025-12-30 US claimed
CN-118006696-B Method for preparing dihydro-beta-ionone by biocatalysis conversion of beta-ionol 南京林业大学 2025-06-17 CN claimed
CN-118497156-A Protein for biocatalytically synthesizing beta-ionol and application thereof 云南中烟工业有限责任公司 2024-08-16 CN claimed
WO-2024124354-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PAIN OR OTHER DISORDERS AIMA INC. (CA) 2024-06-20 WO claimed
CN-118006696-A Method for preparing dihydro-beta-ionone by biocatalysis conversion of beta-ionol 南京林业大学 2024-05-10 CN claimed
CN-117945902-A Preparation method of astaxanthin intermediate 肇庆巨元生化有限公司 2024-04-30 CN claimed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP claimed
EP-4323443-A1 POLYVINYL ALCOHOL COMPOSITIONS WITH EUTECTIC SOLVENTS, ARTICLES THEREOF, AND METHODS OF MAKING SAME The Procter & Gamble Company (US) 2024-02-21 EP claimed
CN-113861089-B Separation and purification method of vitamin A acetate 万华化学集团股份有限公司 2023-12-19 CN claimed
US-20170088793-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES FIRMENICH SA (CH) 2017-03-30 US claimed
US-9550960-B2 Compounds for a controlled release of active molecules FIRMENICH SA (CH) 2017-01-24 US claimed
US-20160137952-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES FIRMENICH SA (CH) 2016-05-19 US claimed
EP-3011000-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES Firmenich SA (CH) 2016-04-27 EP claimed
EP-2986136-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING The Iams Company (US) 2016-02-24 EP claimed
CN-105188400-A Compositions and methods for preventing, reducing, alleviating, or treating idiopathic vomiting IAMS COMPANY 2015-12-23 CN claimed
WO-2014202416-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES FIRMENICH SA (CH) 2014-12-24 WO claimed
WO-2014143539-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING THE IAMS COMPANY (US) 2014-09-18 WO claimed
US-20140271949-A1 Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting THE IAMS COMPANY (US) 2014-09-18 US claimed
US-4877607-A CYCLOHEXYL AND CYCLOHEXENYL ALIPHATIC ALCOHOLS AND KETONES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1989-10-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137952-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES UGT1A3, GUSB, UGT1A4 CYP1A2 26/4885ALDH1A1 62/4885PTGS1 565/4885
US-12509482-B2 3′-ketoglycoside compound for the slow release of a volatile alcohol EBP, MGAT1, MGAT3 CYP1A2 1628/4885ALDH1A1 952/4885PTGS1 1101/4885
US-20170088793-A1 COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES UGT1A3, GUSB, UGT1A4 CYP1A2 26/4885ALDH1A1 62/4885PTGS1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.